Abstract
Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Rubens, R., Kaye, S., Soukop, M. et al. Phase II trial of didox in advanced breast cancer. Br J Cancer 64, 1187–1188 (1991). https://doi.org/10.1038/bjc.1991.488
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.488
This article is cited by
-
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Journal of Cancer Research and Clinical Oncology (2017)
-
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase
Cancer Chemotherapy and Pharmacology (1994)
